erianin and Leukemia-P388

erianin has been researched along with Leukemia-P388* in 1 studies

Other Studies

1 other study(ies) available for erianin and Leukemia-P388

ArticleYear
Antineoplastic agents. 379. Synthesis of phenstatin phosphate.
    Journal of medicinal chemistry, 1998, May-07, Volume: 41, Issue:10

    A structure-activity relationship (SAR) study of the South African willow tree (Combretum caffrum) antineoplastic constituent combretastatin A-4 (1b) directed at maintaining the (Z)-stilbene relationship of the olefin diphenyl substituents led to synthesis of a potent cancer cell growth inhibitor designated phenstatin (3b). Initially phenstatin silyl ether (3a) was unexpectedly obtained by Jacobsen oxidation of combretastatin A-4 silyl ether (1c --> 3a), and the parent phenstatin (3b) was later synthesized (6a --> 3a --> 3b) in quantity. Phenstatin was converted to the sodium phosphate prodrug (3d) by a dibenzyl phosphite phosphorylation and subsequent hydrogenolysis sequence (3b --> 3c --> 3d). Phenstatin (3b) inhibited growth of the pathogenic bacterium Neisseriagonorrhoeae and was a potent inhibitor of tubulin polymerization and the binding of colchicine to tubulin comparable to combretastatin A-4 (1b). Interestingly, the prodrugs were found to have reduced activity in these biochemical assays. While no significant tubulin activity was observed with the phosphorylated derivative of combretastatin A-4 (1d), phosphate 3d retained detectable inhibitory effects in both assays.

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Benzophenones; Cattle; Cell Division; Colchicine; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Leukemia P388; Macromolecular Substances; Molecular Structure; Neisseria gonorrhoeae; Organophosphates; Prodrugs; Protein Binding; Tubulin; Tumor Cells, Cultured

1998